Business Context and Reporting Period
This Form 8-K Current Report was filed by Theriva Biologics, Inc. (TOVX) on March 23, 2026. The filing discloses the outcomes of a Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) regarding the lead clinical candidate VCN-01 for the treatment of metastatic pancreatic adenocarcinoma (PDAC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development milestones and regulatory interactions rather than financial performance.
Material Changes and Clinical Progress
- FDA Agreement: The FDA provided general agreement with the proposed design for a Phase 3 clinical trial of VCN-01 in combination with standard-of-care chemotherapy.
- Trial Design: The Phase 3 design closely tracks the successful VIRAGE Phase 2 trial, which previously met primary endpoints for overall survival (OS), progression-free survival (PFS), and duration of response (DoR).
- Dosing Strategy: The trial will include repeat dosing of VCN-01 in "macrocycles," reflecting data showing greater improvements in patients receiving two doses.
- Regulatory Pathway: The FDA advised that a successful Phase 3 trial could support a potential Biologics Licensing Application (BLA) for VCN-01 in metastatic PDAC.
- Study Parameters: The FDA agreed on the primary endpoint (OS), key secondary endpoints (including PFS), inclusion/exclusion criteria, and the use of an adaptive design.
Guidance, Outlook, and Risks
Management indicated that the Phase 3 trial is designed to optimize timelines and outcomes through an adaptive design. The filing includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, noting that forward-looking statements are subject to risks and uncertainties. The filing does not provide specific financial guidance or discuss material financial risks beyond the inherent uncertainties of clinical development.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical expectations regarding interim analyses.
- Confirm the timeline for the initiation of the Phase 3 trial and patient enrollment targets.
- Review the Company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the adaptive design parameters or sample size re-estimation.